Want to see DE:V3V full AI Analyst Report?
V3V Stock Chart & Stats
€6.05
€0.00(0.00%)
At close: 4:00 PM EST
€6.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.30 - €7.65
Previous CloseN/A
Volume271.00
Average Volume (3M)1.65K
Market Cap
€61.01M
Enterprise Value€77.51M
Total Cash (Recent Filing)€13.84M
Total Debt (Recent Filing)€24.76M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding17,640,104
10 Day Avg. Volume2,079
30 Day Avg. Volume1,645
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€85.00M
Bulls Say, Bears Say
Bulls Say
End-to-end Biobanking Business ModelVita 34's vertically integrated model (collection, lab processing, secure long-term storage) captures multiple service steps and creates recurring storage relationships. This specialization in perinatal biobanking supports steady demand and structural revenue streams if retention and regulation remain supportive.
Material Gross Margin ExpansionA substantial jump in gross margin to ~58% and a positive EBITDA margin indicate the company has improved unit economics and tightened cost structure. If these efficiencies are maintained, they create a durable cushion that improves path to sustained profitability and funds reinvestment or deleveraging over months.
Positive Operating Cash FlowPositive operating cash flow (~€4.5M TTM) shows core operations currently generate liquidity despite accounting losses. This improves near-term solvency, funds working capital needs without immediate capital markets access, and provides a foundation to stabilize operations while pursuing margin and revenue recovery.
Bears Say
Severe Revenue DeclineA 67% TTM revenue decline is a structurally significant deterioration that undermines the business' ability to leverage fixed-cost infrastructure. Sustained top-line contraction reduces revenue visibility, limits economies of scale from improved margins, and heightens the risk the firm cannot cover capital or debt service long term.
Elevated Leverage And Thin EquityHigh leverage (~3.3x debt/equity) and a small equity buffer materially constrain financial flexibility. This increases refinancing and interest-rate risk, reduces capacity to absorb shocks, and makes funding growth or restructuring more costly—pressuring long-term resilience if profitability doesn't recover.
Ongoing Net Losses And Negative ROEPersistent net losses (~€5.9M) and a deeply negative ROE (~-49%) signal the company is destroying shareholder value and struggling to convert operations into sustainable returns. Continued losses will erode capital, complicate access to new equity or debt, and hamper long-term strategic initiatives.
V3V FAQ
What was VITA 34 AG’s price range in the past 12 months?
VITA 34 AG lowest stock price was €3.30 and its highest was €7.65 in the past 12 months.
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is €61.01M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Aug 28, 2026 which is in 52 days.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Overvalued.
Does VITA 34 AG pay dividends?
VITA 34 AG pays a Annually dividend of €0.16 which represents an annual dividend yield of N/A. See more information on VITA 34 AG dividends here
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in DE:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
-58.37%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
VITA 34 AG
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.